Stuttgart - Delayed Quote EUR

Corvus Pharmaceuticals Inc (C17.SG)

Compare
3.7200
+0.0750
+(2.06%)
At close: 9:59:07 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for C17.SG

Recent News: C17.SG

View More
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire 27 days ago
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire last month
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire last month
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn

We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn
Simply Wall St. last month
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Benzinga 2 months ago

Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
PREMIUM
MT Newswires 2 months ago
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire 2 months ago
Tessera gets sickle cell funding; Corvus shares slide on eczema data

Tessera gets sickle cell funding; Corvus shares slide on eczema data
BioPharma Dive 2 months ago
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
GlobeNewswire 2 months ago
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%
Simply Wall St. 2 months ago
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
GlobeNewswire 2 months ago
View More

Related Tickers

1VT.SG Viking Therapeutics Inc
24.54
-11.89%
 
W2J.F Carisma Therapeutics, Inc.
0.3716
-1.80%
 
1VT.DU Viking Therapeutics Inc
24.59
-10.39%
 
W2J.SG CARISMA Therapeutics Inc
0.3740
-2.76%
 
0M4.DU Mersana Therapeutics Inc
0.4683
-0.49%
 
0M4.F Mersana Therapeutics, Inc.
0.4229
-0.33%
 
0M4.BE Mersana Therapeutics Inc
0.4663
-1.71%
 
CYCCP Cyclacel Pharmaceuticals, Inc.
7.83
+12.66%
 
0M4.MU Mersana Therapeutics Inc
0.4915
0.00%
 
OBD.L Oxford BioDynamics Plc
0.5150
-6.70%